BUSINESS UPDATE: Celadon Pharmaceuticals Plc (CEL) Announces Interim Results
Today Celadon announced its Interim Results for the six months ended 30 June 2022, a period of considerable development and growth for the company. Highlights include:
- The completion of seven harvests of high THC cannabis
- Formally requesting that the MHRA schedule an inspection of our facility for our GMP licence
- The commencement of our MHRA-approved chronic pain feasibility study (LVL Health)
- The signing of a new R&D collaboration to explore the development of novel pharmaceutical medicines
Today’s announcement can be read in full by visiting our investor section by clicking here.